Lupin’s arm launches digital therapeutics solution 'LYFE'

24 Jan 2023 Evaluate

Lupin’s wholly-owned subsidiary -- Lupin Digital Health has launched its digital therapeutics solution, LYFE. LYFE is India’s only evidence-based holistic heart care programme that significantly reduces the risk of a heart attack and improves vitals and quality of life for cardiac patients.

Designed by leading Indian cardiologists, LYFE helps patients improve their heart health through doctor-connected online and offline modules. FDA and CE approved wearable devices record vital parameters and notify caregivers and doctors about off-range vitals and emergencies. LYFE's simple and intuitive interface offers medication reminders, 24X7 emergency and ambulance assistance. In addition, LYFE offers expert intervention in the form of dedicated care managers, health coaches and nutritionists. LYFE is an end-to-end solution for cardiac patients, in accordance with protocols designed by their treating cardiologists. Currently available in 10 cities, patients can reach out to their consulting cardiologists to avail LYFE services.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×